For the first quarter of fiscal 2026 (ended March 31, 2026), Dyne Therapeutics reported no revenue and a net loss of $120.9 million, a 4.8% increase from the prior year. Operating loss was $125.3 million, up 2.4% year-over-year. Diluted EPS was -$0.73, improving 30.5% from -$1.05. The company held $753.1 million in cash, $865.1 million in equity, and $149.4 million in long-term debt.
•Net loss of $120.9 million, up 4.8% YoY.
•Operating loss of $125.3 million, up 2.4% YoY.
•Diluted EPS of -$0.73, improved 30.5% YoY.
•Cash and equivalents of $753.1 million; long-term debt of $149.4 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1. Its portfolio also includes duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease
Rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Incorporated in 2017, Dyne Therapeutics is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company focused on discovering and developing therapeutics for neuromuscular diseases. The company is developing a portfolio of muscle disease therapeutics, including programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. It also targets rare skeletal muscle, cardiac, and metabolic muscle diseases using its proprietary FORCE platform, which delivers disease-modifying therapeutics. Dyne Therapeutics is headquartered in Waltham, Massachusetts, and was incorporated in 2017.
On which stock exchange is Dyne Therapeutics (DYN) listed and what currency is used?
Dyne Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DYN. The company trades in United States Dollars (USD), which is the currency of its home country. As a US-based company listed on a major US exchange, its stock is accessible to investors through standard brokerage accounts that trade on Nasdaq.
What sector and industry does Dyne Therapeutics (DYN) belong to?
Dyne Therapeutics operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on research and development of therapies for neuromuscular diseases, which are often genetic or degenerative conditions affecting muscles and nerves. The company's work involves advanced drug discovery and clinical-stage development, typical of biotech firms that aim to bring novel treatments to market.
Where is Dyne Therapeutics (DYN) headquartered and what markets does it serve?
Dyne Therapeutics is headquartered in Waltham, Massachusetts, United States. The company primarily serves the United States market, as indicated by its country and region designation. Its focus is on developing therapeutics for neuromuscular diseases, which affect patients globally, but its operations and clinical programs are based in the US. The company was incorporated in 2017 and has since been advancing its pipeline of muscle disease treatments.
What is the FORCE platform and how does Dyne Therapeutics (DYN) use it?
The FORCE platform is Dyne Therapeutics' proprietary technology used to deliver disease-modifying therapeutics for muscle diseases. This platform is central to the company's approach in developing treatments for conditions like myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. By leveraging FORCE, Dyne aims to target specific muscle tissues and deliver therapies that can modify the course of these neuromuscular diseases. The platform represents a key part of the company's business model, as it enables the development of a diverse portfolio of muscle disease therapeutics.